Pramipexole upregulates dopamine receptor D2 and D3 expression in rat striatum

Journal of Pharmacological Sciences

Volumn 120, Issue 2, 2012, Pages 133-137

  Tokunaga, Naohito ^a,b   Choudhury, Mohammed Emamussalehin ^a   Nishikawa, Noriko ^a   Nagai, Masahiro ^a   Tujii, Tomoaki ^a   Iwaki, Hirotaka ^a   Kaneta, Mika ^a   Nomoto, Masahiro ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

Author keywords

Dopamine receptor; Parkinson's disease; Pramipexole

Indexed keywords

EID: 84868022554     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12096SC     Document Type: Article

References (10)

1. Shioda N, Takeuchi Y, Fukunaga K. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: proteins interacting with the third cytoplasmic loop of dopamine D2 and D3 receptors. J Pharmacol Sci. 2010;114: 25-31.
2. Kvernmo T, Härtter S, Bürger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065-1078.
3. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, et al. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res. 2002;955:138-152.
4. Maj J, Rogóz Z, Margas W, Kata M, Dziedzicka-Wasylewska M. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm. 2000;107:1369-1379.
5. Dziedzicka-Wasylewska M, Rogoz R, Klimek V, Maj J. Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain. J Neural Transm. 1997;104:515-524.
6. Dziedzicka-Wasylewska M, Rogoz R. The effect of prolonged treatment with imipramine on the biosynthesis and functional characteristics of D2 dopamine receptors in the rat caudate putamen. Br J Pharmacol. 1998;123:833-838.
7. Stonehouse AH, Jones FS. Bromocriptine and clozapine regulate dopamine 2 receptor gene expression the mouse striatum. J Mol Neurosci. 2005;25:29-36.
8. Maj J, Rogóz Z, Skuza G, Ko?odziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol. 1997;324:31-37.
9. Barik S, de Beaurepaire R. Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:718-726.
10. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573-580.